ClinicalTrials.gg
CompletedNCT07660653Updated Jun 22, 2026

Resistance-Based Multicomponent Training Plus Nutrition Supplementation for Intrinsic Capacity and Disability Risk in Chinese Rural Older Adults

An interventional study of Routine Health Education and Isocaloric Placebo in Frailty, Sarcopenia and Mobility Limitation, sponsored by Capital University of Physical Education and Sports, China. Completed at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-06-22.

Sponsored by Capital University of Physical Education and Sports, China · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Jun 2025, registered Jun 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
220
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 65 studies in Frailty with a site in China — 26 open to participants now, 28 under way, none of them phase 3. Frailty · China.

Enrollment
9th of 32
220 · median 146
Started
2025
with 9 others
No phase
26 of 65
12 open now
Registered
61st of 65
by date

Among the 65 studies in Frailty with a site in China, this one is the 9th largest by enrollment of the 32 interventional ones that give a count, is one of 10 that started in 2025, is one of 26 with no phase, and was the 61st registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

26 of the 65 studies in Frailty with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Frailty with a site in China, or all of them as a file.
02

Study summary

This study is a five-arm, parallel-group, assessor-blinded randomized controlled trial designed to evaluate the effects of resistance-dominant multicomponent training combined with nutritional supplementation on intrinsic capacity and disability risk among rural Chinese older adults. A total of 220 participants aged 60 years or older with mobility decline, nutritional risk, sarcopenia risk, or pre-frailty/frailty will be randomly assigned to one of five groups: control, nutrition supplementation alone, resistance training alone, resistance training plus nutrition supplementation, or resistance-dominant multicomponent training plus nutrition supplementation. The intervention will last 12 weeks. Exercise interventions will be conducted three times per week, and nutritional supplementation will include leucine-enriched whey protein and vitamin D. The primary outcomes are the Short Physical Performance Battery score, FRAIL score, and activities of daily living/instrumental activities of daily living scores. Secondary outcomes include gait speed, Timed Up and Go test, sit-to-stand performance, handgrip strength, nutritional status, protein intake, serum 25-hydroxyvitamin D, calf circumference, and appendicular skeletal muscle mass index.

Read the detailed description

This study aims to determine whether resistance-dominant multicomponent training combined with leucine-enriched whey protein and vitamin D supplementation can improve intrinsic capacity and reduce disability risk in rural Chinese older adults. The study focuses on the locomotion and vitality domains of intrinsic capacity, which are closely related to mobility function, nutritional status, muscle reserves, and the ability to maintain independent daily living.

Eligible participants will be rural community-dwelling adults aged 60 years or older who present at least one of the following risk characteristics: reduced physical performance, low gait speed, nutritional risk, sarcopenia risk, or pre-frailty/frailty. After baseline assessment, participants will be randomly allocated in a 1:1:1:1:1 ratio to one of five study groups: control group, nutrition supplementation group, resistance training group, resistance training plus nutrition supplementation group, and resistance-dominant multicomponent training plus nutrition supplementation group.

The traditional resistance training program will include progressive functional resistance exercises such as chair sit-to-stand, chair-assisted squat, calf raise, elastic-band knee extension, elastic-band hip abduction, elastic-band rowing, wall push-up, and shoulder press. The resistance-dominant multicomponent training program will use resistance training as the core component and will additionally include balance, gait, aerobic, flexibility, and breathing relaxation exercises. Exercise sessions will be conducted three times per week for 12 weeks.

The nutritional supplementation will consist of approximately 20 g/day whey protein, 2.5-3.0 g/day total leucine, and 800-1000 IU/day vitamin D3. The supplement will be administered twice daily. On training days, one dose will be taken within 30 minutes to 2 hours after exercise, and another dose after breakfast. On non-training days, the supplement will be taken after breakfast and dinner.

Outcome assessments will be performed at baseline and at week 12. The primary outcomes are the Short Physical Performance Battery score, FRAIL score, and activities of daily living/instrumental activities of daily living scores. Secondary outcomes include 4-meter gait speed, Timed Up and Go test, five-times sit-to-stand test, 30-second chair stand test, handgrip strength, Mini Nutritional Assessment Short Form score, daily protein intake, serum 25-hydroxyvitamin D, body mass index, calf circumference, appendicular skeletal muscle mass index, and quality of life. Safety outcomes include renal function, blood calcium, falls, musculoskeletal injury, gastrointestinal symptoms, and other adverse events.

03

Conditions studied

  • Frailty
  • Sarcopenia
  • Mobility Limitation
  • Nutritional Risk

Keywords

  • Rural older adults
  • Resistance training
  • Multicomponent exercise
  • Whey protein
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged 60 years or older.
  2. Rural residents who have lived in the study area for at least 6 months and have no plan for long-term absence during the study period.
  3. Able to walk independently or with a cane for a short distance.
  4. Meeting at least one of the following risk characteristics: Short Physical Performance Battery score of 9 or lower, usual gait speed of 0.8 m/s or lower, Mini Nutritional Assessment Short Form score of 11 or lower, SARC-F score of 4 or higher, possible sarcopenia according to the Asian Working Group for Sarcopenia 2019 criteria, or FRAIL score of 1 to 3.
  5. Able to understand the study requirements and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Unstable cardiovascular or cerebrovascular events within the past 6 months.
  2. Severe uncontrolled hypertension, defined as resting systolic blood pressure of 180 mmHg or higher or diastolic blood pressure of 110 mmHg or higher.
  3. Severe cognitive impairment that prevents understanding of or cooperation with the study procedures.
  4. Severe osteoarticular disease or neurological disease affecting exercise safety.
  5. Severe renal dysfunction, such as estimated lower than 30 mL/min/1.73 m², or considered unsuitable for protein supplementation by the study physician.
  6. Hypercalcemia, active kidney stones, or to vitamin D supplementation.
  7. Allergy to whey protein or any component of the nutritional supplement.
  8. Regular use of protein powder, beta-hydroxy-beta-methylbutyrate, creatine, or other nutritional supplements that may affect muscle metabolism within the past 3 months.
  9. Participation in another interventional study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
220 participants (actual)

Study arms

  • Placebo comparator
    Control Group

    Participants in this group will receive routine health education and an isocaloric placebo without structured exercise training for 12 weeks.

    Behavioral: Routine Health Education · Dietary Supplement: Isocaloric Placebo

  • Experimental
    Nutrition Supplementation Group

    Participants in this group will receive leucine-enriched whey protein and vitamin D supplementation without structured exercise training for 12 weeks.

    Dietary Supplement: Leucine-Enriched Whey Protein and Vitamin D Supplementation

  • Experimental
    Resistance Training Group

    Participants in this group will receive supervised progressive resistance training three times per week for 12 weeks and an isocaloric placebo.

    Dietary Supplement: Isocaloric Placebo · Behavioral: Progressive Resistance Training

  • Experimental
    Resistance Training Plus Nutrition Group

    Participants in this group will receive supervised progressive resistance training three times per week for 12 weeks combined with leucine-enriched whey protein and vitamin D supplementation.

    Dietary Supplement: Leucine-Enriched Whey Protein and Vitamin D Supplementation · Behavioral: Progressive Resistance Training

  • Experimental
    Resistance-Dominant Multicomponent Training Plus Nutrition Group

    Participants in this group will receive supervised resistance-dominant multicomponent training three times per week for 12 weeks combined with leucine-enriched whey protein and vitamin D supplementation.

    Dietary Supplement: Leucine-Enriched Whey Protein and Vitamin D Supplementation · Behavioral: Resistance-Dominant Multicomponent Training

Interventions

  • BehavioralRoutine Health Education

    Participants will receive routine health education during the 12-week study period. The health education will include general advice on healthy aging, physical activity safety, balanced diet, fall prevention, and chronic disease self-management. Participants will not receive structured exercise training or active nutritional supplementation as part of this intervention.

  • Dietary supplementIsocaloric Placebo

    Participants will receive an isocaloric placebo that is similar to the active nutritional supplement in appearance, taste, packaging, and administration frequency. The placebo will be administered during the 12-week study period.

  • Dietary supplementLeucine-Enriched Whey Protein and Vitamin D Supplementation

    Participants will receive a nutritional supplement containing approximately 20 g/day whey protein, 2.5 to 3.0 g/day total leucine, and 800 to 1000 IU/day vitamin D3. The supplement will be administered twice daily for 12 weeks. On training days, one dose will be taken within 30 minutes to 2 hours after exercise, and the other dose will be taken after breakfast. On non-training days, the supplement will be taken after breakfast and dinner.

  • BehavioralProgressive Resistance Training

    Participants will complete supervised progressive resistance training three times per week for 12 weeks, with each session lasting 45 to 60 minutes. Exercises will include chair sit-to-stand, chair-assisted squat, calf raise, elastic-band knee extension, elastic-band hip abduction, elastic-band rowing, wall push-up, and shoulder press. Training intensity will progress from RPE 3-4/10 during weeks 1-4, to RPE 5-6/10 during weeks 5-8, and RPE 6-7/10 during weeks 9-12.

  • BehavioralResistance-Dominant Multicomponent Training

    Participants will complete supervised resistance-dominant multicomponent training three times per week for 12 weeks, with each session lasting 50 to 65 minutes. The program will use resistance training as the core component and will also include balance, gait, aerobic, flexibility, and breathing relaxation exercises. Each session will include approximately 25 to 30 minutes of resistance training, 8 to 10 minutes of balance and gait training, 8 to 10 minutes of aerobic exercise, and 5 minutes of stretching and relaxation.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Short Physical Performance Battery Score at Week 12

    The Short Physical Performance Battery will be used to assess lower-extremity physical performance, including standing balance, 4-meter gait speed, and five-times sit-to-stand performance. Total scores range from 0 to 12, with higher scores indicating better physical performance.

    Time frame: Baseline and Week 12

  2. Change From Baseline in FRAIL Score at Week 12

    The FRAIL scale will be used to assess frailty status. The scale includes fatigue, resistance, ambulation, illness, and loss of weight. Scores range from 0 to 5, with higher scores indicating greater frailty risk.

    Time frame: Baseline and Week 12

  3. Change From Baseline in Activities of Daily Living Score at Week 12

    Activities of daily living will be assessed to evaluate basic self-care ability in daily life. Higher scores indicate better basic daily living function.

    Time frame: Baseline and Week 12

  4. Change From Baseline in Instrumental Activities of Daily Living Score at Week 12

    Instrumental activities of daily living will be assessed to evaluate more complex daily living abilities. Higher scores indicate better instrumental daily living function.

    Time frame: Baseline and Week 12

07

Study locations

1 site
  • Rural Community Sites in Jiaozuo, Henan
    Jiaozuo, Henan 454000, China
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because the study involves personal health information from rural older adults, and no formal data-sharing plan or participant consent for public data sharing has been established.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Jan 2026, 6 months.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's 6 months is below that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2026
First posted
Jun 22, 2026
StartActual
Jun 18, 2025
Primary completionActual
Jan 15, 2026
CompletionActual
Jan 31, 2026
Last update
Jun 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07660653
Lead sponsor
Capital University of Physical Education and Sports, China
Responsible party
Yongzhao Fan (Associate Professor, Capital University of Physical Education and Sports, China) — Principal investigator
First posted
Jun 22, 2026
Start date
Jun 18, 2025
Primary completion
Jan 15, 2026
Completion
Jan 31, 2026
Last update
Jun 22, 2026

Study contacts

yongzhao f, PhD
principal investigator · Henan Normal University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion